| DB ID | MyCo_5772 |
| Title | Variable Correlation between Bronchoalveolar Lavage Fluid Fungal Load and Serum-(1,3)-β-d-Glucan in Patients with Pneumocystosis-A Multicenter ECMM Excellence Center Study |
| Year | 2020 |
| PMID | 33271743 |
| Fungal Diseases involved | Pneumocystosis |
| Associated Medical Condition | None |
| Genus | Pneumocystis |
| Species | jirovecii |
| Organism | Pneumocystis jirovecii |
| Ethical Statement | None |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Bronchoalveolar lavage fluid (BALF) |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Negative |
| Biomolecule | Protein |
| Geographical Location | None |
| Cohort | Patients were retrospectively enrolled between 1 January 2015 to 31 December 2019. Inclusion of the cases required that BAL fluid was tested with qPCR and a minimum of one serum for BDG was tested within a time frame of 7 days before or after BAL sampling. Coinfection with other invasive fungal infections were collected in parallel. A total of 147 patients were enrolled in this study, including 117 cases of Pneumocystis pneumonia (PCP) and 30 cases of Pneumocystis carriage (PCC). |
| Cohort No. | 147 |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Pneumocystis jirovecii pneumonia (PCP) is one of the most prevalent invasive fungal infections. It is still one of the main infections revealing AIDS in western countries. In parallel, it is now mainly diagnosed in non-HIV patients, such as patients treated for hematological malignancies, solid organ transplant recipients, or patients treated with immunosuppressive therapies. The clinical presentation and biological features associated with PCP are different in HIV and non-HIV patients, suggesting that the disease has a different pathophysiology with a more acute disease presentation and an increased mortality in non-HIV patients. |
| Technique | PCR |
| Analysis Method | qRT-PCR |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | FDA approved Fungitell assay, qRT-PCR |
| Up Regulation Down Regulation | Negative |
| Sequence Data | None |
| External Link | None |
